1. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations

   • Marcello Maugeri-Saccà
   • Maddalena Barba
   • Luigi Di Lauro

   Review 13 August 2014 Pages: 227 - 235

2. Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review

   • S. J. Ioannides
   • P. L. Barlow
   • D. Porter

   Review 14 August 2014 Pages: 237 - 248

   

3. Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs

   • Amy Plotkin
   • Claude-Henry Volmar
   • Dorraya El-Ashry

   Preclinical study 17 August 2014 Pages: 249 - 263

   

4. High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF-β-dependent epithelial-mesenchymal transition in breast cancer

   • Cheng Zhang
   • Yong Han
   • Chengchao Shou

   Preclinical study 17 August 2014 Pages: 265 - 281

   

5. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer

   • Julie M. Madden
   • Kelly L. Mueller
   • Julie L. Boerner

   Preclinical study 17 August 2014 Pages: 283 - 293

   

6. Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

   • Bharath Rudraraju
   • Marjolein Droog
   • Carlo Palmieri

   Preclinical study 22 August 2014 Pages: 295 - 309

   

7. Outcomes of solid palpable masses assessed as BI-RADS 3 or 4A: a retrospective review

   • Stephanie K. Patterson
   • Colleen H. Neal
   • Kuanwong Watcharotone

   Preclinical study 24 August 2014 Pages: 311 - 316

   

8. Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy

   • Rei Mimoto
   • Tadashi Kobayashi
   • Hiroshi Takeyama

   Preclinical study 26 August 2014 Pages: 317 - 324

   

9. Circulating tumor cells in non-metastatic triple-negative breast cancer

   • Mandar Karhade
   • Carolyn Hall
   • Anthony Lucci

   Preclinical Study Open access 28 August 2014 Pages: 325 - 333

   

10. Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate?

    • David K. Woolf
    • Anwar R. Padhani
    • Andreas Makris

    Clinical trial 17 August 2014 Pages: 335 - 343

    

11. Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer

    • Andreas D. Hartkopf
    • Diana Stefanescu
    • Florin-Andrei Taran

    Clinical trial 24 August 2014 Pages: 345 - 351

    

12. Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures

    • Chi-Cheng Huang
    • Shih-Hsin Tu
    • Eric Y. Chuang

    Clinical Trial 27 August 2014 Pages: 353 - 370

    

13. Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients

    • Isabel T. Rubio
    • Martin Espinosa-Bravo
    • Vicente Peg

    Clinical trial 28 August 2014 Pages: 371 - 380

    

14. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival

    • Mala Pande
    • Melissa L. Bondy
    • Abenaa M. Brewster

    Epidemiology 10 August 2014 Pages: 381 - 387

    

15. Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program

    • Maegan V. Prummel
    • Susan J. Done
    • Anna M. Chiarelli

    Epidemiology 10 August 2014 Pages: 389 - 399

    

16. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

    • T. Byrski
    • T. Huzarski
    • S. A. Narod

    Epidemiology 17 August 2014 Pages: 401 - 405

17. Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer

    • Claudette Falato
    • Julie Lorent
    • Theodoros Foukakis

    Epidemiology 17 August 2014 Pages: 407 - 414

    

18. Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study

    • E. H. Allott
    • C.-K. Tse
    • M. A. Troester

    Epidemiology 24 August 2014 Pages: 415 - 421

    

19. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells

    • Yifang Wei
    • Xiaofeng Lai
    • Jian Zhang

    Brief Report 10 July 2014 Pages: 423 - 431

    

20. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

    • Vakaramoko Diaby
    • Georges Adunlin
    • Alberto J. Montero

    Brief Report 11 July 2014 Pages: 433 - 441

    

21. Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

    • Vakaramoko Diaby
    • Georges Adunlin
    • Alberto J. Montero

    Erratum 28 August 2014 Pages: 443 - 443

22. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation

    • Mary K. Askren
    • Misook Jung
    • Bernadine Cimprich

    Brief Report 21 August 2014 Pages: 445 - 455

    

23. Unvalidated antibodies and misleading results

    • David Rimm
    • Kurt Schalper
    • Lajos Pusztai

    Letter to the Editor 03 August 2014 Pages: 457 - 458

24. Author’s response to “Letter to the editor: unvalidated antibodies and misleading results”

    • S. Muenst
    • A. Tzankov
    • S. D. Soysal

    Rebuttal Letter 01 August 2014 Pages: 459 - 462